Abstract

One aspect of the invention concerns a method for characterizing the internal three-dimensional organization of a biological tissue sample comprising a plurality of types of biological elements (201, 202), said method having the following steps: For at least one type of biological elements (201, 202, 203, 204) of interest among the plurality of types of biological elements (201, 202, 203, 204), automatic or semi-automatic segmentation in each image (IZ) from a stack of images (I3D), of at least one region containing at least one biological element (201, 202, 203, 204) having as type, the type of biological elements (201, 202,203, 204) of interest, the stack of images (I3D) having been acquired by Z-series imaging by automated ultramicrotomy under scanning electron microscopy and including a plurality of images (IZ) each acquired in a plane perpendicular to a depth axis (Z) and each associated with a position on the depth axis (Z), the plurality of images (IZ) being ordered by increasing position in the stack of images (I3D, 102); Characterization of a set of biological elements (201, 202, 203, 204) having as type the type of biological elements (201, 202, 203, 204) of interest, by calculation, for each biological element (201, 202, 203, 204) from the set of biological elements (201, 202, 203, 204), of at least one indicator (301, 302) relating to the structure, the morphology, the size, the polarity, the texture, the constitution, the orientation, a surface area, the alignment, the convergence, the density, the convexity or the concavity of the biological element (201, 202, 203,204), from each corresponding segmented region (104); Comparison between the indicators (301, 302) calculated for the set of biological elements (201, 202, 203, 204).

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06T 7/00 - Image analysis
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

opt12iNN) within a detection zone (100) surrounding the mobile device (D), and a control system (30) configured to impose, on the mobile device (D), a modified trajectory (T') enabling it to reach the target position. The modified trajectory is dependent on the optimal trajectory and on the position of each intruding mobile device at each instant t during movement.

IPC Classes  ?

• G05D 1/242 - Means based on the reflection of waves generated by the vehicle
• G05D 1/633 - Dynamic obstacles
• G08G 5/80 - Anti-collision systems

Abstract

The present disclosure concerns an ultrasound 3D imaging probe (200) for imaging vascular activity dynamically at a microscopic scale in an organ of a body of a living being, the probe (200) comprising : - a mosaic ultrasound array (100) comprising a plurality of polygonal transducer element pads, each pad (101) comprising a set of transducer elements (102) distributed on a substrate (103), each transducer element (102) being configured to acquire at least a backscattered ultrasound wave from the organ following an ultrasound emission in said organ; - a support frame (10) comprising an intern surface intended to be placed facing said body; - each polygonal transducer element pad (101) being located and attached in a removable manner on said internal surface of the support frame (10).

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2) and human interferon-omega 1 (IFN-ω1), two subtypes of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2 and IFN-ω1. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 and IFN-ω1 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to a bio-assimilable polymer microcapsule loaded with at least one active substance and comprising at least one micrometric opening. The disclosure also relates to a method for obtaining said capsule, and to this capsule for its use in the treatment of a pathology, in particular cancer or myopathy.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin

Abstract

A method for bonding a layer of elastomeric material to an aluminum substrate includes treating a surface of the aluminum substrate so as to roughen the surface of the aluminum substrate, treating the surface by an argon plasma, exposing the surface to a plasma, in the presence of a gaseous chemical precursor chosen from the epoxides, acrylics, alkenes, alkynes and imides, until a deposit of a chemical species with a thickness of between 5 nanometers and 110 nanometers is obtained, contacting the layer of elastomeric material with the surface of the aluminum substrate, and vulcanizing the layer of elastomeric material. The exposing is carried out at a low pressure of between 10−2 mbar and 10−5 mbar.

IPC Classes  ?

• B32B 38/00 - Ancillary operations in connection with laminating processes
• B32B 15/06 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of rubber
• B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
• B32B 38/10 - Removing layers, or parts of layers, mechanically or chemically

Abstract

A method for recycling concrete waste from construction and/or deconstruction, including at least one step of microwave processing of concrete blocks, at least one step of mechanical processing, and at least one step of carbonation of recycled concrete aggregates and/or recycled concrete fines; and a recycling installation for carrying out the recycling method and to recycled concrete aggregates obtained by the steps of microwave processing of concrete blocks and mechanical processing.

IPC Classes  ?

• C04B 18/167 - Recycled materials, i.e. waste materials reused in the production of the same materials
• B01J 2/22 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
• C04B 20/00 - Use of materials as fillers for mortars, concrete or artificial stone according to more than one of groups and characterised by shape or grain distributionTreatment of materials according to more than one of the groups specially adapted to enhance their filling properties in mortars, concrete or artificial stoneExpanding or defibrillating materials
• C04B 40/00 - Processes, in general, for influencing or modifying the properties of mortars, concrete or artificial stone compositions, e.g. their setting or hardening ability
• C04B 40/02 - Selection of the hardening environment

Abstract

A measurement system is configured to determine a pressure of a liquid of interest having compressibility km flowing in a channel of radius rint, which are selected such that the product km×rint is less than or equal to 12.5×10−11 mm/Pa. The system includes a flow actuator for flowing the liquid of interest in the channel at a Mach number less than or equal to 0.3, a thermal measurement device for measuring a temperature of the liquid of interest flowing in the channel, and a processing unit configured to determine the pressure from the temperature measured and a predetermined calibration function.

IPC Classes  ?

• G01L 11/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by means not provided for in group or
• G01J 5/00 - Radiation pyrometry, e.g. infrared or optical thermometry
• G01K 1/143 - SupportsFastening devicesArrangements for mounting thermometers in particular locations for measuring surface temperatures
• G01K 3/08 - Thermometers giving results other than momentary value of temperature giving differences of valuesThermometers giving results other than momentary value of temperature giving differentiated values
• G01K 13/02 - Thermometers specially adapted for specific purposes for measuring temperature of moving fluids or granular materials capable of flow
• G01L 27/00 - Testing or calibrating of apparatus for measuring fluid pressure

Abstract

The present invention relates to the treatment of an arthritic disease such as rheumatoid arthritis with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 35/74 - Bacteria
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention relates to compounds of formula (I): as well as stereoisomeric forms, mixtures of stereoisomeric forms, and salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in claim 1. Compounds of formula (I) are particularly useful for preparing coordination metal or metalloid complexes for the catalysis of ring opening polymerisation of cyclic esters. The invention relates to compounds of formula (I): as well as stereoisomeric forms, mixtures of stereoisomeric forms, and salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in claim 1. Compounds of formula (I) are particularly useful for preparing coordination metal or metalloid complexes for the catalysis of ring opening polymerisation of cyclic esters.

IPC Classes  ?

• C07F 3/06 - Zinc compounds
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes

Abstract

The present invention relates to Li-rich positive electrode active material comprising a layered structure and a disordered rock-salt structure exhibiting high capacity and excellent cycling stability.

IPC Classes  ?

• C01G 53/506 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese of the type (MnO2)n-, e.g. Li(NixMn1-x)O2 or Li(MyNixMn1-x-y)O2 containing lithium and cobalt with the molar ratio of nickel with respect to all the metals other than alkali metals higher than or equal to 0.5, e.g. Li(MzNixCoyMn1-x-y-z)O2 with x ≥ 0.5 with the molar ratio of nickel with respect to all the metals other than alkali metals higher than or equal to 0.8, e.g. Li(MzNixCoyMn1-x-y-z)O2 with x ≥ 0.8

Abstract

The invention relates to a cyclodextrin derivative which comprises: - glycosidic subunits of chemical structure (4): (4), - optionally at least one glycosidic subunit of chemical structure (5): (5), the total number of glycosidic subunits of chemical structure (4) and chemical structure (5) being equal to an integer n of between 5 and 30, and at least 2 x of the x of the glycosidic subunits of chemical structure (4) being different from one another. The invention relates to a process for producing the CD derivative and to the applications thereof.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• C08L 5/16 - CyclodextrinDerivatives thereof
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

The invention relates to a contrast agent which comprises a gadolinium compound in an effective amount, the gadolinium compound comprising a complexing group in the form of an N-hydroxylamine, which can be protonated or deprotonated as a function of the pH, and another complexing group in the form of an imine (preferably a pyridine). Preferred gadolinium compounds are the compounds of chemical structures (A) and (B): The invention also relates to a method for acquiring medical-imaging images which involves the administration of the contrast agent, and to the use thereof in the diagnosis of tissue acidosis.

IPC Classes  ?

• A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
• A61K 49/10 - Organic compounds
• C07D 257/00 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms

Abstract

Inventors have firstly demonstrated that the transcriptomic signature of PTENpc-/-medmed cells is enriched in human MSPC signature, associated to metastases and ADT resistance. Using scRNAseq specifically with sorted PTENpc-/-LSCmedcells, they identified three distinct LSCmedclusters and showed that castration favors the emergence of the most stem-like LSCmedsubpopulation by cell plasticity. In the latter, they identified the transcription factor FOSL1/AP-1 and the kinase PIM1 as relevant therapeutic targets, and they showed that combined inhibition using JQ1, a BET/AP-1 inhibitor, and CX-6258, a pan-PIM kinase inhibitor, efficiently prevents PTENpc/-LSCmedcell growth in organoids. These findings were confirmed in the human prostate HPV10 cell line here identified as a robust model of Club/Hillock cells. Combined drug delivery to castrated PTEN-null mice induced a significant prostate weight decrease associated with the reduction of histopathological phenotypes and dramatically altered organoid-formation capacity of LSCmed cells sorted from these tumors. Accordingly, the drug combination significantly delayed tumor growth of MSPC-like human PC-3 cells subcutaneously injected into castrated immunodeficient mice. Altogether, this work shows a new therapeutic potential of combined FOSL1 and PIM1 targeting to prevent, or at least delay, the growth of MSPC-like cells. Accordingly, the invention relates to i) an inhibitor of FOSL1 and ii) an inhibitor of PIM1, as a combined preparation for use in the treatment of prostate cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

An electrolyte composition for a Zinc metal electrochemical device said electrolyte composition comprising water, a zinc salt, and an additive of formula (I), its use and an electrochemical device comprising said electrolyte.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 4/24 - Electrodes for alkaline accumulators
• H01M 10/36 - Accumulators not provided for in groups

Abstract

22 electrochemical device said electrolyte composition comprising water, a zinc salt, and a combination of additives, wherein the combination of additives comprises an organic additive and an additive of formula (I), its use and an electrochemical device comprising said electrolyte.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/36 - Accumulators not provided for in groups

Abstract

The present disclosure proposes a method and apparatus for imaging at a microscopic scale a region of an organ of a human or animal, allowing the use of a 2D subsampled ultrasound probe while providing 3D ULM images with high resolution usually obtained only with a full 2D array matrix, by sorting the detected microbubbles and keeping only the microbubbles corresponding to the spots belonging to the main lobe of the Point Spread Function (PSF) of the microbubble and removing the phantom microbubbles corresponding to the spots belonging to the side lobes. It is also possible to provide a 3D non-invasive imaging of the microvascular flow of the region of an organ, such as a brain in-vivo, with high resolution and high sensitivity.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2), one subtype of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2), one subtype of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/56 - IFN-alpha
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-omega 1 (IFN-ω1), one subtype of type I interferons that play important roles in innate and adaptive immunity. The antibodies can also be used for the diagnosis of auto-immune diseases and viral infections by detecting the presence or level of IFN-ω1 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to bromotyrosine derivatives compounds for use in treating protein misfolding diseases.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A method for synthesizing at least one crystalline layer of manganese oxides that can contain zinc, of formula ZnxMnyOz, where x is greater than or equal to 0, y is greater than 0, and z is greater than 0, the method being implemented in a chamber of a low-pressure plasma reactor, kept between 10 Pa and 105 Pa, the method comprising forming a plasma discharge from a plasma-generating gas; adding, in the form of a nebulizate, a predetermined amount of a manganese precursor; adding a reactive gas so as to create oxygen vacancy defects in the layer of manganese oxides, and/or so as to maintain a controlled redox environment; synthesizing and depositing, on a substrate, the at least one crystalline layer of manganese oxides that can contain zinc, these operations being carried out at a substrate temperature of 400° C. or less, advantageously 200° C. or less.

IPC Classes  ?

• C23C 16/40 - Oxides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• H01M 4/04 - Processes of manufacture in general
• H01M 4/50 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese

Abstract

uimxxS cc mm) at every point of spatial position (x, z); g) construction of an image from the dynamic confocal signals.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01N 29/44 - Processing the detected response signal
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

ui ξξξξ ω ξξξξ ω xxxx M ξξξξ ωx xxxx MM). The spatio-frequential basis ξ ensures an independence between the spatial and sequential data and makes it possible to demonstrate a chromato-angular memory effect associated with the field reflected by the object. The scattering screen makes it possible to increase the base resolution of the acquisition probe.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01N 29/44 - Processing the detected response signal
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 8/08 - Clinical applications

Abstract

The present invention relates to a method of screening for a molecule mimicking interleukin 34 (IL-34) bone regulation activity based on the binding of IL-34 to bone morphogenetic proteins (BMPs), which comprises the steps of: 1) reacting a candidate molecule and BMPs under suitable conditions, 2) detecting the binding of the candidate molecule to BMPs and optionally a bone regulation activity, 3) comparing the binding and optionally the bone regulation activity detected in step 2) to a control, and 4) selecting a molecule capable of binding to BMPs and inducing osteoblast differentiation and activities without activating osteoclast functions. The present invention also relates to a molecule mimicking IL-34 bone regulation activity based on the binding of IL-34 to BMPs, obtained by the method, and to a pharmaceutical composition comprising the molecule and a pharmaceutically acceptable carrier.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to an electric power supply system configured to output a voltage from a capacitor arm comprising 6+2n capacitors. Each capacitor of rank i has a first terminal forming a terminal of rank i of the capacitor arm, and a second terminal forming a terminal of rank i+1 of the capacitor arm, i being a natural number between 1 and 6+2n. The power supply system furthermore comprises: for each capacitor of rank i, i ranging from 2 to 6+2n-1, a respective generic module, each generic module comprising a switch arm the ends of which are connected to the terminals of the capacitor of rank i, a branch comprising a DC voltage source and an inductor in series, a first end of the branch being connected to the centre tap of the switch arm; a first and second terminating module, each comprising a voltage source, a first switch arm and a second switch arm, the centre taps of the first and second arms being connected to a first, respectively second, branch comprising a respective inductor. Terminals of the first terminating module are connected to the terminals of rank 1, 2, 3 of the capacitor arm. Terminals of the second terminating module are connected to the terminals of rank 6+2n-1, 6+2n, 6+2n+1 of the capacitor arm. Second ends of the branches of the generic modules are connected and the switch arms are controlled such that the currents passing through the terminals of the capacitor arm are balanced.

IPC Classes  ?

• H02M 1/00 - Details of apparatus for conversion
• H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load

Abstract

The present invention relates to a method for producing 1-chloro-2,2-difluoroethane (HCFC-142 or F142), by reacting gaseous 1,1,2-trichloroethane (HCC-140 or T112) and/or 1,2-dichloroethylene (HCO-1130-E or 1,2-DCE) with gaseous anhydrous hydrogen fluoride (HF), in a reactor in the presence of nanodiamonds, which is economically feasible at industrial scale and which provides high yield and selectivity.

IPC Classes  ?

• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• C07C 19/12 - Acyclic saturated compounds containing halogen atoms containing fluorine and chlorine having two carbon atoms

Abstract

The present invention relates to the treatment of the COVID-19, here, the inventors generated potent non-neutralizing pan-SARS-CoV-2 mAb, notably the antibody C10, targeting a conserved region of the virus. Noteworthy, C10 demonstrated remarkable efficacy in recognizing nearly all known variants of the virus and effectively binding infected cells. Leveraging this pan-SARS-CoV-2 mAb, they have engineered CAR-T cells capable of efficiently killing lung epithelial cells infected with the virus. Overall, their work identifies a pan-SARS-Cov-2 able to target bona fide infected cells and provides a proof-of-concept for the potential use of CAR-T cell therapy in combating SARS-CoV-2 infections. Their findings also highlight the potential of non-neutralizing mAbs in mediating immune protection against emerging infectious diseases. Thus, the present invention relates to anti-spike antibodies, particularly in a purified form or in an isolated form and their use to treat SARS-CoV-2. Particularly, the present invention is defined by the claims.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

iiiiiiii111112122 are selected from F, Cl, Br, S, O or I.

IPC Classes  ?

• C09K 5/16 - Materials undergoing chemical reactions when used

Abstract

Herein disclosed are compounds of formula (I), which are metabolized into, or act as, analogues of oncosterone (6-oxo-cholestan-3β,5α-diol), a metabolite produced by tumor cells overexpressing cholesterol-5,6-epoxide hydrolase (ChEH) and/or expressing 11β-hydroxysteroid dehydrogenase type 2 (HSD2) and the glucocorticoid receptor (GR), neutralizing the signaling pathway and tumorigenicity of oncosterone. The compounds of formula (I) herein disclosed are thus useful in preventing and/or treating cancers, in subjects, preferably humans, overexpressing cholesterol-5,6-epoxide hydrolase (ChEH) and/or expressing 11β-hydroxysteroid dehydrogenase type 2 (HSD2) and the glucocorticoid receptor (GR). In addition, being analogues of oncosterone, some of the compounds of formula (I) are also useful in the prevention and/or treatment of cancers expressing the glucocorticoid receptor (GR).

Abstract

The present invention pertains to the provision of conjugates for the detection of target molecules by using mass spectrometry imaging. In particular, disclosed herein a particularly innovative conjugate for the detection of target molecules that is usable in the four following techniques of MSI: MALDI-MSI, DESI-MSI, nano-DESI- MSI and SpiderMass (MSI).

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The invention relates to a system (101) for measuring a photoinduced deformation of a sample, the system comprising a Michelson interferometer (103), wherein the Michelson interferometer comprises a first light source and means for acquiring and converting the optical interference signal into an electrical signal, a second light source (201), an arbitrary signal generator (205) configured to modulate the brightness of the second light source (201) at a frequency, and a signal-processing unit (211) for processing the electrical signal. The second beam (203) illuminates the sample, and the processing unit (211) is configured to determine the amplitude of the deformation of the sample from the electrical signal.

IPC Classes  ?

• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

The present invention relates to a method for manufacturing acrylated epoxidised plant oil particles comprising the following steps: a) mixing acrylated epoxidised plant oil with at least one solvent and in the presence of at least one photoinitiator; b) optionally mixing the solution after step a) with a solution S1; c) mixing the solution obtained after step a) or after optional step b) with an aqueous solution comprising at least one surfactant in order to obtain droplets; d) exposing said droplets to a UV light; e) retrieving the acrylated epoxidised plant oil particles obtained after step d).

IPC Classes  ?

• C07D 301/00 - Preparation of oxiranes
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis

Abstract

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I). The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/52 - Purines, e.g. adenine
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• C07D 471/04 - Ortho-condensed systems
• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems

Abstract

A process for preparing a polyethylene bearing a terminal ketone function or a copolymer of ethylene and a 1,3-diene and optionally a vinylaromatic compound which contains more than 50 mol % of ethylene and bears a terminal ketone function is provided. The process comprises a polymerization reaction of the monomers in the presence of a borohydrido-neodymocene complex and an organomagnesium reagent, followed by a coupling reaction with a compound containing a nitrile function, and then a hydrolysis reaction.

IPC Classes  ?

• C08F 10/02 - Ethene
• C08F 36/06 - Butadiene

Abstract

The invention relates to a method for preparing a multilayer semiconductor system, the method comprising the following steps: (a) depositing, on a monocrystalline substrate, a thin layer that comprises a material comprising at least one element from column IIIB and elements from column VB, referred to as IIIB-VB materials, which material is epitaxied; (b) depositing, on the thin layer comprising the IIIB-VB material, a metal source of a d-block transition metal, preferably under a chalcogen gas atmosphere, wherein the chalcogen is preferably not oxygen and is preferably sulphur; and wherein the metal source of the d-block transition metal preferably comprises more than 99.9% of the transition metal expressed as a percentage by weight relative to the total weight of the metal source.

IPC Classes  ?

• C30B 23/02 - Epitaxial-layer growth
• C30B 25/18 - Epitaxial-layer growth characterised by the substrate
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 33/02 - Heat treatment

Abstract

According to one aspect, the present description relates to a system (100) for detecting the seatbelt-wearing state of at least one passenger of at least one first vehicle (301), the system comprising detection means configured to acquire, according to a linear and/or circular polarisation, at least one first polarised image of a field of view of the first vehicle, consisting of a plurality of pixels, and determining at least one enriched image with n channels of the field of view of the first vehicle, n ≥ 1, wherein the enriched image consists of a plurality of pixels comprising n values, at least one of which values is a polarisation value determined from pixel values of the at least one first polarised image. The system further determines, from the at least one enriched image, a seatbelt-wearing state of the at least one passenger of the first vehicle.

IPC Classes  ?

• G06V 10/147 - Details of sensors, e.g. sensor lenses
• B60N 2/00 - Seats specially adapted for vehiclesArrangement or mounting of seats in vehicles
• B60R 21/00 - Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
• B60R 22/48 - Control systems, alarms, or interlock systems, for the correct application of the belt or harness
• G06V 20/56 - Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
• G08G 1/00 - Traffic control systems for road vehicles
• G08G 1/01 - Detecting movement of traffic to be counted or controlled
• G08G 1/04 - Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors

Abstract

The invention relates to an electric power supply system configured to deliver a DC voltage from a first end and a second end of a capacitor arm. The capacitor arm has 4+2n capacitors, n being a natural number, each capacitor being connected to the ends of a respective switch arm. The power supply system is such that, from the first end of the capacitor arm to the second end of the capacitor arm, i being a natural number between 1 and 4+2n: wherein for first capacitors of rank i=2 or i=4+2n-1, respectively, the midpoint of the corresponding switch arm is connected to a first branch comprising a first DC voltage source configured to deliver a voltage having a first value V and a first inductor in series, the first branch additionally being connected to the first end of the capacitor arm or to the second end of the capacitor arm, respectively; and wherein for second capacitors of odd rank i different from 4+2n-1, the midpoint of the switch arm corresponding to the capacitor of rank i and the midpoint of the switch arm corresponding to the capacitor of rank i+3 are connected by a second branch comprising a second DC voltage source configured to deliver a voltage having a value 2 x V and a second inductor in series.

IPC Classes  ?

• H02M 1/00 - Details of apparatus for conversion
• H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load

Abstract

The present invention relates to a method for preparing a fluoropyridine that comprises fluorinating a halopyridine with hydrogen fluoride in the gas phase and in the presence of nanodiamonds, at least part of the surface of which contains sp2 carbon atoms and hydrogenated and/or oxygenated surface functions, such that there is formed a compound of formula (I) and an acid chosen from HCl, HBr and a mixture thereof.

IPC Classes  ?

• C07D 213/61 - Halogen atoms or nitro radicals

Abstract

The invention relates to a device (1) for the detection of spin waves, comprising - a magnetic film (2) adapted to guide a spin wave excited by an excitation means (5), - a magneto-resistive element (3), wherein the magneto-resistive element (3) is coupled to the magnetic film (2) by magnetic coupling, wherein the magneto-resistive element (3) is configured to exhibit a magneto-resistive effect in response to a magnetization state of the magnetic film (2), the magnetization state of at least a part of the magneto-resistive element (3) varying as a function of the guided spin wave, the device (1) further comprising: - measurement means (6) configured to detect an electrical signal corresponding to the magneto-resistive effect The invention also relates to a method for the detection of spin waves.

IPC Classes  ?

• G01R 33/09 - Magneto-resistive devices
• G01R 33/12 - Measuring magnetic properties of articles or specimens of solids or fluids
• H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
• B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance

Abstract

The present invention relates to a measurement circuit (16) of a stabilizer of a quantum error correction code for logical qubits, each logical qubit comprising one or several qubits being encoded in neutral atoms with interactions mediated by Rydberg states, the stabilizer being measured on one ancilla qubit and several data qubits, the measurement circuit (16) comprising, for each data qubit, a device (18) comprising a coupling unit (20) adapted to apply a laser pulse symmetrically on both the data qubit and the ancilla qubit, the laser pulse having an amplitude and a phase chosen to have a probability of occurrence of the Rydberg hopping inferior to 0.4 when both qubits are excited by said laser pulse.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers

Abstract

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng/mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng/mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention pertains to the provision of conjugates for the detection of target molecules using mass spectrometry imaging (MSI).

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present inventors have shown that specific benzene sulfonamide thiazole compounds (I) have the ability to induce an early endoplasmic reticulum stress. These compounds also lead to cancerous cells growth inhibition and death. The present inventors have shown that specific benzene sulfonamide thiazole compounds (I) have the ability to induce an early endoplasmic reticulum stress. These compounds also lead to cancerous cells growth inhibition and death.

IPC Classes  ?

• C07D 277/46 - Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 35/00 - Antineoplastic agents
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 277/40 - Unsubstituted amino or imino radicals
• C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07F 9/6539 - Five-membered rings

Abstract

A method for assembling of suspensions inside a channel, such as to form aggregates or agglomerates of particles and to expel a composition including the aggregates or agglomerates from the channel in order to produce a part by additive manufacturing. The method is preferably performed on colloidal suspensions.

IPC Classes  ?

• C04B 35/14 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silica
• B28B 1/00 - Producing shaped articles from the material
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 40/10 - Pre-treatment
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• C04B 35/10 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on aluminium oxide
• C04B 35/624 - Sol-gel processing

Abstract

Devices and methods for processing decision data including a decision tree and an input path, each node of the decision tree being associated with a respective feature of a feature set. The method includes an inheritance processing, as a function of a current universal set. The inheritance processing includes: determining that the edge verifies a first criterion relative to a consistency of the edge with a corresponding edge of the input path relative to the same feature as those of the current node, and then performing a first sub-inheritance processing as a function of the child node; and/or determining that the edge verifies a second criterion, and then performing a second sub-inheritance processing as a function of the child node and the current universal set, such that the first sub-inheritance processing and the second sub-inheritance processing allows including features in the set for explaining the input path.

IPC Classes  ?

• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound

Abstract

The invention relates to an orthopaedic screw (1) for the sacroiliac joint (71), the screw comprising a core (2) extending between a distal end (1a) and a proximal end (1b), and a first thread (3), wherein the core (1) comprises a central conical portion (21) having a first slope (α1), a distal portion (20) having a second slope (α2) smaller than the first slope (α1), and a proximal portion (22) having a third slope (α3) smaller than the first slope (α1), and wherein the first thread (3) has a height (D) that increases from the proximal end (21b) towards the distal end (21a) of the central conical portion (21), over a retaining portion (210) of the central conical portion (21), so as to enhance screw retention, in particular in osteoporotic bone.

IPC Classes  ?

• A61B 17/86 - Pins or screws

Abstract

The invention relates to a porous solid containing at least 90% by weight, relative to the total weight of the porous solid, of a polyurethane polyester copolymer. The invention also relates to the method for preparing the porous solid. The invention also relates to a medical implant material consisting of the porous solid and collagen, and to the method for preparing this material. The invention also relates to a medical implant made of the medical implant material. Finally, the invention relates to the use of the porous solid or of the medical implant material for the production of a medical implant.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body
• A61F 2/30 - Joints
• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/42 - Polycondensates having carboxylic or carbonic ester groups in the main chain
• C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
• C08L 75/06 - Polyurethanes from polyesters
• C09D 175/06 - Polyurethanes from polyesters
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 27/56 - Porous or cellular materials

Abstract

The present invention is directed to method of determining whether a subject is at risk of developing insulin resistance, particularly for advance alert of T2D and or CVD onset in obese and non-obese subject, by detecting the branched-chain amino acids (BCAAs) present in an urine sample (uBCAAs) of the subjects. The present invention also relates to a method for determining the need of a dietary/nutritional supplement for a subject involving said uBCAAs biomarkers. Finally, the invention is directed to kit comprising the biochemical network allowing the uBCAAs detection and process for the preparation of said biochemical networks as diagnostic biomarker.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• G01N 1/34 - PurifyingCleaning

Abstract

The present disclosure relates to a method for preparing a site-specific recombination polynucleotide molecule derived from the attP site of the bacteriophage mv4 and to a kit for such site-specific recombination. The kit can be used to transform procaryote hosts to integrate any polynucleotide sequence of interest.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention relates to an imager (1) comprising: - an array of spectral filters formed of a repeating pattern of spectral filters; - an array of polarisers; - an array of photosensors; and - a processing device designed so that, for each of the different spectral bands, it forms at least one image of pixels having positions in the image that correspond, respectively, to predefined positions (i, j) of a mask (M) in the array of photosensors, wherein each of the pixels is calculated on the basis of the brightnesses measured by the photosensors for the stated spectral band contained in the mask (M) at the position (i, j) of the pixel. The pattern of spectral filters is designed such that, for each of the different spectral bands and for all of the predefined positions (i, j) of the mask (M), the photosensors for the stated spectral band have an isobarycentre located in a central virtual box (PVC) of the mask (M) having the same size as the boxes of the array of photosensors, and each of the predefined positions (i, j) of the mask (M) is offset from another predefined position (i, j) by a column or row of the array of photosensors.

IPC Classes  ?

• G01C 21/02 - NavigationNavigational instruments not provided for in groups by astronomical means
• G02B 5/20 - Filters
• G01J 4/04 - Polarimeters using electric detection means
• G01C 11/02 - Picture-taking arrangements specially adapted for photogrammetry or photographic surveying, e.g. controlling overlapping of pictures
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/28 - Investigating the spectrum

Abstract

The present invention relates to a technique for compensating for the non-linear distortion of an electroacoustic transducer (T) based on a post-processing operation applied to the electrical signal delivered by the transducer by means of a non-linearizing harmonic component (M) arranged downstream of same.

IPC Classes  ?

• H04R 19/00 - Electrostatic transducers

Abstract

The present invention relates to the field of the treatment of cancer. In this study, the inventors found that VDAC2 is heterogeneously expressed in MM cells. VDAC2 protein expression correlated with BAK but not with BAX protein levels. Transient silencing of VDAC2, but not VDAC1 or VDAC3, sensitized MM cells to intrinsic mitochondrial apoptosis signals, alongside with the induction of pre-activated BAK and the increase of global, MCL1 and BCL2 mitochondrial priming. They also found a that a VDAC2 compound, efesevin recapitulated the sensitization effect of VDAC2 knock-down on BH3 mimetics apoptotic response. This novel VDAC2 modulator sensitized MM cells to BH3 mimetics targeting MCL1 (S63845) or BCL2 (Venetoclax) without modifying BAK or BAX protein expression. The efficiency of the VDAC2 modulator was directly correlated with the levels of VDAC2 protein. To better understand the VDAC2/BAK interplay, The inventors generated VDAC2 KO myeloma cells. VDAC2 KO cells exhibited an important decrease of BAK protein expression while BAX remained unchanged. Accordingly, VDAC2 KO cells completely lost their mitochondrial priming. Interestingly, they also found that BAK KO myeloma cells displayed decreased levels of VDAC2. The reciprocal regulation between VDAC2 and BAK was dependent on both the proteasome and lysosome degradation pathways. Thus, the present invention relates to a combination of a VDAC2 modulator and a BH3- mimetics compound for use in the treatment of a cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to methods and pharmaceutical composition for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as estrogen receptor-positive (ER+) cancers, like ER+ breast cancer (ER+BC). The invention relates to the combined use of an inhibitor of the methyltransferase-like protein 3 (METTL3) and an inhibitor of the nuclear DNA topoisomerase I (TOP1) for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as ER+ cancers. The inhibition of METTL3 increases the sensitivity of ER + breast cancer cells to Topoisomerase-1 inhibitor.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a process for preparing a metal-organic framework (MOF) comprising a step of synthesizing the metal-organic framework (MOF) which comprises bringing at least one aluminum alkoxide into contact with at least one at least bidentate organic ligand in the presence of an aqueous solvent, whereby a colloidal suspension comprising said MOF and also an alcohol is obtained, and a step of recovering the synthesized MOF.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention relates to a process for preparing a metal-organic framework (MOF) comprising a step of synthesizing the metal-organic framework (MOF) which comprises bringing at least one aluminum alkoxide into contact with at least one at least bidentate organic ligand in the presence of an aqueous solvent, whereby a colloidal suspension comprising said MOF and also an alcohol is obtained, and a step of coating a support with said colloidal suspension, whereby a thin layer of said MOF is deposited on said support.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating

Abstract

The present invention concerns the treatment of Fibrotic interstitial lung diseases (Fibrotic ILDs) and particularly Progressive pulmonary fibrosis (PPF) such as idiopathic lung fibrosis (IPF). In particular inventors develop antisense oligonucleotides targeting HSPB5 and study their effects on the development of experimental pulmonary fibrosis. Specific antisense oligonucleotides (ASO) were designed and screened in vitro, based on their ability to inhibit both human and murine HSPB5 expression. One of them, ASO22, was selected by its capacity to inhibit TGF-β1-induced expression of HSPB5 and additional key markers of fibrosis such as PAI-1, collagen, fibronectin and α-SMA in fibroblastic human CCD-19Lu cells as well as PAI- 1 and α-SMA in pulmonary epithelial A549 cells. Intra-tracheal or intravenous administration of ASO22 in bleomycin-induced pulmonary fibrotic mice decreased HSPB5 expression and reduced fibrosis as measured by the decrease in pulmonary remodeling, collagen accumulation and Acta2 and Col1a1 expression. Altogether, these results suggest a real interest of using an antisense oligonucleotide strategy targeting HSPB5 for the treatment of pulmonary fibrosis.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present application relates to a method of treating a respiratory viral infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that depletes plasmacytoid dendritic cells. Another object of the present application relates to a kit of part comprising said agent and at least one further therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a respiratory viral infection in a subject in need thereof.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The invention relates to an imaging optical system (11), comprising a primary mirror (M1), a secondary mirror (M2), a tertiary mirror (M3), and an exit pupil (PS). Light rays (21, 22, 23) originating from a scene are consecutively reflected by these three mirrors in the direction of the exit pupil. A light ray (21, 22, 23) from the scene is thus split into an initial segment (210, 220, 230), a first intermediate segment (211, 221, 231), a second intermediate segment (212, 222, 232), and a terminal segment (213, 223, 233). M1 and M2 are oriented such that the second intermediate segment (232) of a parabasal ray (23) of the system intersects the initial segment (230) of the parabasal ray. M2 and M3 are oriented such that the first intermediate segment (231) of the parabasal ray of the system intersects the terminal segment (233) of the parabasal ray. An intermediate image plane (PI) is located between M1 and M2 or between M2 and M3.

IPC Classes  ?

• G02B 17/06 - Catoptric systems, e.g. image erecting and reversing system using mirrors only
• G02B 23/06 - Telescopes, e.g. binocularsPeriscopesInstruments for viewing the inside of hollow bodiesViewfindersOptical aiming or sighting devices involving prisms or mirrors having a focusing action, e.g. parabolic mirror

Abstract

The present invention relates to an electromediated process for separating at least one first-row transition metal M1, such as nickel, from a liquid sample. The liquid sample preferably originates from a battery. The invention further relates to an electromediated process for regenerating copper and/or a primary amine from a complex comprising copper and said primary amine, an electromediated process for stripping a metal ion from a complex comprising said metal and a primary amine and an electromediated process for recovering at least one first-row transition metal M1 and/or at least one primary amine from a complex comprising said metal and said primary amine.

IPC Classes  ?

• C22B 3/42 - Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C25C 1/08 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of iron group metals, refractory metals or manganese of nickel or cobalt
• C25C 1/12 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
• C22B 3/06 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic acid solutions
• C22B 15/00 - Obtaining copper

Abstract

The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:1, preferably is VEGF222/NF and consists of SEQ ID NO:1.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and/or neuroprotection in a subject. Such VEGR-1 inhibitors include small organic molecules, peptides, antibodies, antibody fragments, antibody mimetics, or nucleic acids. Also, compositions, pharmaceutical compositions, medicaments and kits of parts that include VEGFR-1 inhibitors and their use for promoting myelination and/or neuroprotection in a subject.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: —a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; —a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b); 15—a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention concerns a material of formula (I): The present invention concerns a material of formula (I): wherein: A is Na or Li or a mixture of Na and Li, The present invention concerns a material of formula (I): wherein: A is Na or Li or a mixture of Na and Li, 1 < x < 3 , 0 ≤ y ≤ 1 , 0 ≤ z ≤ 1 M is an electro-active transition element or a mixture of at least two electro-active transition elements, M′ is a non electro-active element or a mixture of at least two non electro-active elements, and the material of formula (I) presents a V/Z ratio varying from 212 Å3 to 246 Å3.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/04 - Processes of manufacture in general
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium

Abstract

The present application relates to the storage of gases, using a porous composite based on a porous matrix and an organic compound confined in solid form within pores of the matrix with a diameter of less than 10 nm.

IPC Classes  ?

• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating
• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen

Abstract

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 31/04 - Antibacterial agents
• C12N 9/50 - Proteinases
• C12N 9/52 - Proteinases derived from bacteria

Abstract

To apply the invention to treat a part made of used plastic comprising an organic filler and an inorganic filler, (A) pieces of the part to be treated are admixed with at least one water-immiscible organic solvent (S1), which is a good solvent for the plastic and is capable of solvating the organic filler and the plastic and of releasing the inorganic filler; (B) an aqueous solution of an agent for extracting the inorganic filler is added to the mixture obtained, the aqueous solution being capable of transferring the inorganic filler by liquid-liquid extraction from the mixture to the aqueous solution, the inorganic filler then being in the dissolved state in the aqueous solution; (C) the two immiscible phases obtained are collectively admixed with a water-immiscible solvent (S2) which is miscible with the solvent (S1) and is a poor solvent for the plastic and a good solvent for the organic filler, in order to precipitate, in at least one solid phase, the plastic in dispersed form, while leaving the organic filler in the mixture of solvents (S1) and (S2), constituting an organic liquid phase, and the inorganic filler remaining dissolved in the aqueous solution, constituting an aqueous phase; the solid plastic phase is recovered by solid-liquid separation; separated by their density difference, the organic filler and the inorganic filler respectively are isolated from each of the organic and aqueous phases obtained.

Abstract

The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 40/13 - B-cells
• C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07K 14/54 - Interleukins [IL]
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP/PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A device for controlling and protecting a power transistor, comprising: a nominal switching circuit for the transistor, a short-circuit detection circuit which keeps the transistor in the conducting state and detects an increase or decrease in the voltage VGS of the transistor relative to reference voltages representative of a short-circuit of the transistor; a protection circuit which discharges the gate of the transistor after the detection of a short-circuit; and a circuit for measuring and controlling the nominal switching circuit, the short-circuit detection circuit and the protection circuit.

IPC Classes  ?

• H03K 17/0812 - Modifications for protecting switching circuit against overcurrent or overvoltage without feedback from the output circuit to the control circuit by measures taken in the control circuit
• G01R 31/26 - Testing of individual semiconductor devices
• H03K 17/18 - Modifications for indicating state of switch

Abstract

The invention concerns a compound of formula (I) wherein R, R1and R2are independently selected form the group consisting of: a hydrogen atom, a halogen atom, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carboxyl group, an amido group comprising from 1 to 10 carbon atoms, and an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R3, R4, R5and R6 are independently selected form the group consisting of: a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an alkoxy group comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carbonate group from 1 to 10 carbon atoms, a carboxyl group, and a cyano group, for use as neuroprotectants, or in the treatment of disorders with reduced NAD metabolism.

IPC Classes  ?

• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Control tissues and different lesions of either adenomyosis or endometriosis were exposed in vitro during 24 hours either to vehicle (DMSO) or different doses of BYL719 or ST420, a PIK3CA inhibitor. Inventors observed that lesions treated with DMSO had a higher recruitment of the PIK3CA pathway compared to healthy endometrium. Importantly, both inhibitors were able to shut down the phosphorylation of AKT. They concluded that PIK3CA inhibition is a good therapeutic target for patients with endometriosis and adenomyosis. They also investigated the role of the PIK3CA pathway in myoma, another benign uterine condition. They observed that either alpelisib or ST420 were able to inhibit the pathway in myoma. They concluded that myoma demonstrate PIK3CA/AKT pathway activation with somatic mutation and are accessible to targeted treatment. Accordingly, the invention relates to method for treating uterine disease in a subject in need thereof comprising a step of administrating the subject with a therapeutically effective amount of PIK3CA inhibitor such as compound of formula (I), or a deuterated or tritiated form of the compound of formula (I), BYL719.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for producing a web of fibres comprising fibres of a copolymer based on the repeating unit derived from vinylidene fluoride (VDF), by electrospinning a solution of the fluorinated polymer. The invention also relates to the webs of fibres that can be obtained using said method. Lastly, the invention relates to the various applications of said webs of fibres as a filtration device for filtering air and/or liquid.

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
• D01D 1/02 - Preparation of spinning solutions
• D01D 5/00 - Formation of filaments, threads, or the like
• D01F 6/12 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of halogenated hydrocarbons from polymers of fluorinated hydrocarbons
• D01F 6/32 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds comprising halogenated hydrocarbons as the major constituent
• D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning

Abstract

Translating bacterial-based therapies to clinical success has yet been proven challenging, facing targeting inconsistencies, formulation issues and immune system noncompliance that can lead up to sepsis. To counter these limitations, the invention provides the Smart Polymer Shield (SPS) for the encapsulation of individual live cells.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl group as leaving group, which allows all side products to be separated from the radiolabelled product. Said compounds are therefore useful tools in a method for synthesizing iodo- or astatoarryl compounds, in particular radioiodo- or radioastatoaryl compounds. The present invention relates to a method for synthesizing iodo- or astatoaryl compounds comprising the reaction of an arylsulfonium compound with an iodide or astatide salt, respectively. The invention also relates to arylsulfonium compounds as such. The invention also concerns a method of synthesizing an iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoraryl compound.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 17/093 - Preparation of halogenated hydrocarbons by replacement by halogens
• C07C 45/63 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by introduction of halogenPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by substitution of halogen atoms by other halogen atoms
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 247/06 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated and containing rings
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 381/12 - Sulfonium compounds
• C07D 213/61 - Halogen atoms or nitro radicals
• C07D 333/76 - Dibenzothiophenes
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

A method for determining implementation parameters of an electronic circuit configured to process an input signal. The electronic circuit includes an analog portion having a plurality of parameterisable analog primitives and a digital portion having a plurality of parameterisable digital primitives. The digital portion is coupled to the analog portion by at least one analog-digital converter and/or at least one analog comparator with or without hysteresis. The method includes a phase of joint learning of the parameters of the plurality of parameterisable analog primitives and of the parameters of the plurality of parameterisable digital primitives.

IPC Classes  ?

• G06F 30/38 - Circuit design at the mixed level of analogue and digital signals
• G06F 30/337 - Design optimisation
• G06F 30/373 - Design optimisation
• G06N 3/084 - Backpropagation, e.g. using gradient descent

Abstract

The present disclosure relates to a method for configuring a system for classifying images of a target domain on the basis of a classification of images of at least one source domain, the method comprising: - encoding of pairs of texts, each pair comprising a text of the source domain and a text of the target domain, by a neural network-based encoder, previously trained and configured to encode text and image data pairs; - training a first neural network to determine parameters of a first augmentation function, this training being done by minimising a first distance D between the text of the encoded target domain and the text of the source domain of a single pair, encoded by the text encoder and augmented by the first augmentation function; - training of the classification system, the training being carried out on the images of the source domain encoded by the trained image encoder and then transformed by the first augmentation function.

IPC Classes  ?

• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations

Abstract

The invention relates to a mould for manufacturing at least one marking pad for marking at least one test sample, the mould comprising a body having at least: - a base provided with a first main face and a second main face; - at least one flank extending from the base to at least partly form a peripheral edge of the base, wherein the first main face of the base thus forms a bottom of the body, at least one hundred holes extending in at least one region of the base so as to open at a first end on the first main face and to be blind at a second end opposite the first end, wherein the holes are arranged in a predetermined pattern. The invention also relates to the corresponding pad and method.

IPC Classes  ?

• B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
• B29C 33/40 - Plastics, e.g. foam or rubber
• B29C 33/42 - Moulds or coresDetails thereof or accessories therefor characterised by the shape of the moulding surface, e.g. ribs or grooves

Abstract

The present invention relates to compositions, and in particular to pharmaceutical compositions, comprising, or even consisting of, a suspension of bacteriophages of the class Caudoviricetes, the bacteriophages having lytic activity against at least one Gram-positive bacterial strain, at a titer of at least 108 PFU/mL, in a dispersing medium comprising, or even consisting of: - at least one non-ionic surfactant, and in particular a single non-ionic surfactant, selected from the polysorbate family, at a molar concentration greater than its critical micelle concentration, but not exceeding 2 mg/mL, and/or the poloxamer family, at a concentration ranging from 0.005% (w/v) to 30% (w/v); - one or more neutral salts formed from a pair of monovalent ions, the total molar concentration of which is in the range from 75 to 160 mM; - a buffer mixture imparting to the composition a pH from 6.0 to 7.9, and preferentially from 7.0 to 7.5, typically selected from hydrogen phosphate ion/dihydrogen phosphate, citric acid/citrate ion and citric acid/hydrogen phosphate ion ion pairs, wherein the molarity of the buffer mixture is in the range from 4 mM to 100 mM; - water, wherein the composition comprises less than 0.9 bacterial endotoxin units per mL and a total protein concentration of less than 0.09 mg/mL, and wherein the bacteriophage suspension in the dispersing medium has an osmolality of between 150 mOsm/kg and 600 mOsm/kg; the invention also relates to associated methods and uses.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61M 3/00 - Medical syringes, e.g. enemataIrrigators
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to hybrid polymer/filler materials prepared from bipyridine derivatives functionalised with acrylate groups of formula (I) and/or metal complexes comprising said functionalised bipyridine derivatives, wherein the polymer comprising the functionalised bipyridines can form a shell around the filler, as well as to the method for preparing same and the uses thereof.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C08G 79/14 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing two or more elements other than carbon, oxygen, nitrogen, sulfur, and silicon

Abstract

mesmesmesmesmes-thmes-th, triggers (33) a measurement event (4).

IPC Classes  ?

• H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
• H04N 25/707 - Pixels for event detection

Abstract

The present invention relates to a crosslinkable two-component composition comprising: - a component A comprising: - a compound having one of the following formulae (Ia) or (Ib): - at least one (meth)acrylate compound M1; - a component B comprising at least one compound having one of the following formulae (C) or (D).

IPC Classes  ?

• C08K 5/45 - Heterocyclic compounds having sulfur in the ring
• C08K 5/50 - Phosphorus bound to carbon only
• C09J 4/00 - Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
• C09J 133/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen

Abstract

The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly (oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Estimating the state of energy for a particular time, which includes: Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; estimating a maximum energy that can be delivered by the cell, assuming that the temperature and the current remain constant; and Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; estimating a maximum energy that can be delivered by the cell, assuming that the temperature and the current remain constant; and subtracting the estimated total delivered energy from the estimated maximum energy.

IPC Classes  ?

• G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/3842 - Arrangements for monitoring battery or accumulator variables, e.g. SoC combining voltage and current measurements
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte

Abstract

Method for monitoring the operation and/or the geometry of a wind turbine in motion comprising a tower and several blades extending from a rotor hub, the method comprising: (a) acquisition with a three-dimensional acquisition apparatus of a plurality of scans representing at least partially the wind turbine; (b) segmenting the scans to identify at least portions corresponding to the blades; (c) generating a 3D representation by at least aligning and denoising the scans with respect to a common frame of reference associated with the wind turbine and compensating for relative motion between the three-dimensional acquisition apparatus and the wind turbine; (d) computing, based on the 3D representation, at least one geometric or operational parameter and/or computing at least one geometric transformation between at least one representative part of one blade and the corresponding representative part of at least one of the other blades and computing at least one wind turbine geometric or operational parameter based on the at least one computed geometric transformation.

IPC Classes  ?

• F03D 17/00 - Monitoring or testing of wind motors, e.g. diagnostics

Abstract

The present disclosure concerns sodium-phosphate niobium bronzoïds and bronzes having the following formula: Na2Nb4P2O16 and NaNb3P2O13, and their manufacture, comprising the following steps: Annealing a mixture of precursors M1; Grinding the annealed mixture M1; Pelletizing the ground mixture M1 to obtain a pellet P1; Annealing the pellet P1; wherein M1 comprises a niobium precursor, a phosphate precursor, and a sodium precursor.

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• C01G 33/00 - Compounds of niobium
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The present disclosure concerns lithium-phosphate niobium bronzoTds and bronzes having either of the following formula: Li2Nb4P2O16 or LiNb3P2O13 and the process for their manufacture, comprising the following steps: Providing a sodium-phosphate niobium bronzoid or bronze; mixing and grinding the sodium-phosphate niobium bronzoid or bronze with a Li-comprising precursor to obtain a mixture M2; pelletizing the mixture M2 to obtain a pellet P2; annealing the pellet P2; grinding the pellet to obtain a powder W2; washing and drying the powder W2.

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• C01G 33/00 - Compounds of niobium
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

T-cell acute lymphoblastic leukemias (T-ALL) are aggressive hematological malignancies associated with poor clinical outcome. TP53 alterations (TP53Alt) were rarely identified in T-ALL at diagnosis and their prognostic impact remains unclear. In a cohort of 476 adults and pediatric T-ALL, TP53Alt were observed in 4% of cases and were associated with chemoresistance and poor prognosis. APR-246, a small compound which restores wild-type configuration to mutated p53, showed efficacy in T-ALL harboring TP53 mutations. More importantly, in TP53 germline T-ALL, Notch 1 pathway gain of function mutations were associated with substantial sensitivity to APR-246. Mechanistically, Notch 1 activation via p53 downregulation and subsequent ferroptosis induction led to preferential APR-246 sensitivity. Given that Notch 1 pathway oncogenic activation is present in more than 70% of T-ALLs, these observations pave the way for promising perspectives in T-ALL treatment which could benefit from the Achilles heel associated with Notch 1 activation sensitizing leukemia cells to APR-246-induced ferroptosis, thus extending the use of APR-246 in T-ALL beyond TP53 alterations.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 35/02 - Antineoplastic agents specific for leukemia
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to chemically modified adeno-associated (AAV) viruses and their use in gene therapy.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors

Abstract

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

IPC Classes  ?

• C07K 14/525 - Tumour necrosis factor [TNF]
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

A device includes a magnetic tunnel junction; a conductive spacer with low spin-orbit coupling and high mean orbital moment diffusion length; and a conductive track able to generate an orbital moment current from a charge current and having a weak spin-orbit coupling.

IPC Classes  ?

• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• H10N 50/01 - Manufacture or treatment
• H10N 50/10 - Magnetoresistive devices

Abstract

The present invention relates to a method for manufacturing a part (1) with improved resistance to oxidation and high-temperature corrosion, comprising at least the deposition of a non-cracked crystalline β-Yb2Si2O7 environmental barrier layer (7) on an at least partially ceramic matrix composite material (3), wherein the environmental barrier layer is deposited by chemical vapour deposition from a gas phase comprising a precursor mixture of (a) a compound A of formula SiClxHy, in which x is an integer from 1 to 4 and y is an integer from 0 to 3, with x + y = 4, and (b) elementary ytterbium or ytterbium(III) chloride, and wherein, during deposition, a temperature between 1100°C and 1300°C and a pressure of 150 mbar or less are imposed.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• C23C 16/40 - Oxides
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

2277 crystalline environmental barrier layer (7) onto an at least partially ceramic matrix composite material (3), said environmental barrier layer being deposited by chemical vapor deposition of organometallic compound(s), at an imposed temperature, during the deposition, of between 1200°C and 1400°C and an imposed pressure of less than or equal to 40 mbar.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• C23C 16/40 - Oxides
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

One aspect of the invention relates to a pulse generator (4) for generating a current pulse on an output branch (46) upon receipt of a trigger command, comprising: • a first half-bridge (431, 432) and a second half-bridge (433, 434), the latter comprising bidirectional switches; • an inductor (45) connected between the two half-bridges; and • a controller configured, according to different configurations of the half-bridges, to charge the inductor (45) and discharge it into the output branch (46).

IPC Classes  ?

• H03K 3/53 - Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback
• H03K 3/57 - Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback the switching device being a semiconductor device
• H03K 17/06 - Modifications for ensuring a fully conducting state
• H03M 1/08 - Continuously compensating for, or preventing, undesired influence of physical parameters of noise
• H03K 17/16 - Modifications for eliminating interference voltages or currents
• H03K 17/66 - Switching arrangements for passing the current in either direction at willSwitching arrangements for reversing the current at will

Abstract

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA/ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and/or RHOA inhibitor.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to a combination of at least two different resorcinol derivatives, wherein one resorcinol derivative is a 4-alkylresorcinol of formula (I), a pharmaceutically acceptable salt, and/or a solvate thereof, and one resorcinol derivative is a 4-azoaryl resorcinol of formula (II), a pharmaceutically acceptable salt and/or solvate thereof, said combination for use as an antibacterial agent, a pharmaceutical composition comprising said combination, said pharmaceutical composition for use as a medicament, and said pharmaceutical composition for use in the treatment of bacterial or infectious diseases, in particular caused by Gram-positive bacteria.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/425 - Thiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 31/04 - Antibacterial agents